Global amyotrophic lateral sclerosis treatment market will reach $762.3 million by 2027, growing by 5.8% annually over 2020-2027 owing to the increasing geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies.
Highlighted with 80 tables and 67 figures, this 139-page report “Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Region.
Based on Treatment Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Medication
o Riluzole (Rilutek)
o Radicava (Edaravone)
o Tiglutik (Thickened Riluzole)
o Nuedexta
• Stem Cell Therapy
• Other Treatments
Based on ALS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Sporadic ALS
• Familial ALS
Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AB Science SA
Amylyx Pharmaceuticals Inc.
Biogen Inc.
Biohaven Pharmaceutical Holding Co., Ltd.
BrainStorm Cell Limited
Corestem, Inc.
F.Hoffmann-La Roche AG
Ionis Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Global Market by Treatment Type 40
3.1 Market Overview by Treatment Type 40
3.2 Medication 42
3.3 Stem Cell Therapy 44
3.4 Other Treatments 45
4 Segmentation of Global Market by ALS Type 46
4.1 Market Overview by ALS Type 46
4.2 Sporadic ALS 48
4.3 Familial ALS 49
5 Segmentation of Global Market by Distribution Channel 50
5.1 Market Overview by Distribution Channel 50
5.2 Hospital Pharmacies 52
5.3 Retail Pharmacies 53
5.4 Online Pharmacies 54
5.5 Other Distribution Channels 55
6 Segmentation of Global Market by Region 56
6.1 Geographic Market Overview 2020-2027 56
6.2 North America Market 2020-2027 by Country 60
6.2.1 Overview of North America Market 60
6.2.2 U.S. 63
6.2.3 Canada 66
6.2.4 Mexico 68
6.3 European Market 2020-2027 by Country 70
6.3.1 Overview of European Market 70
6.3.2 UK 73
6.3.3 France 75
6.3.4 Germany 77
6.3.5 Spain 79
6.3.6 Italy 81
6.3.7 Russia 83
6.3.8 Rest of European Market 85
6.4 Asia-Pacific Market 2020-2027 by Country 87
6.4.1 Overview of Asia-Pacific Market 87
6.4.2 China 90
6.4.3 Japan 92
6.4.4 India 95
6.4.5 Australia 97
6.4.6 South Korea 99
6.4.7 Rest of APAC Region 101
6.5 South America Market 2020-2027 by Country 103
6.5.1 Argentina 106
6.5.2 Brazil 108
6.5.3 Chile 110
6.5.4 Rest of South America Market 112
6.6 MEA Market 2020-2027 by Country 113
6.6.1 UAE 116
6.6.2 Saudi Arabia 118
6.6.3 South Africa 120
6.6.4 Other National Markets 122
7 Competitive Landscape 123
7.1 Overview of Key Vendors 123
7.2 New Product Launch, Partnership, Investment, and M&A 126
7.3 Company Profiles 127
AB Science SA 127
Amylyx Pharmaceuticals Inc. 129
Biogen Inc. 130
Biohaven Pharmaceutical Holding Co., Ltd. 131
BrainStorm Cell Limited 132
Corestem, Inc. 133
F.Hoffmann-La Roche AG 134
Ionis Pharmaceuticals, Inc. 135
Mitsubishi Tanabe Pharma Corporation 136
Otsuka Pharmaceutical Co., Ltd. 137
Sun Pharmaceutical Industries Ltd. 138
RELATED REPORTS 139
Table 1. Snapshot of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Balanced Perspective, 2020-2027 19
Table 2. Growth Rate of World GDP, 2020-2022 22
Table 3. Main Product Trends and Market Opportunities in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 32
Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 40
Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication by Type, 2017-2027, $ mn 43
Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 46
Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 50
Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Region, 2017-2027, $ mn 57
Table 9. Leading National Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020 and 2027, $ mn 59
Table 10. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 62
Table 11. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 65
Table 12. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 65
Table 13. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 65
Table 14. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 67
Table 15. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 67
Table 16. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 67
Table 17. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 69
Table 18. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 69
Table 19. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 69
Table 20. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 72
Table 21. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 74
Table 22. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 74
Table 23. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 74
Table 24. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 76
Table 25. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 76
Table 26. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 76
Table 27. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 78
Table 28. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 78
Table 29. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 78
Table 30. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 80
Table 31. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 80
Table 32. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 80
Table 33. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 82
Table 34. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 82
Table 35. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 82
Table 36. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 84
Table 37. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 84
Table 38. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 84
Table 39. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe by Country, 2017-2027, $ mn 86
Table 40. APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 89
Table 41. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 91
Table 42. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 91
Table 43. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 91
Table 44. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 94
Table 45. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 94
Table 46. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 94
Table 47. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 96
Table 48. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 96
Table 49. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 96
Table 50. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 98
Table 51. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 98
Table 52. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 98
Table 53. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 100
Table 54. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 100
Table 55. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 100
Table 56. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of APAC by Country/Region, 2017-2027, $ mn 102
Table 57. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 105
Table 58. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 107
Table 59. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 107
Table 60. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 107
Table 61. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 109
Table 62. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 109
Table 63. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 109
Table 64. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 111
Table 65. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 111
Table 66. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 111
Table 67. MEA Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 115
Table 68. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 117
Table 69. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 117
Table 70. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 117
Table 71. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 119
Table 72. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 119
Table 73. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 119
Table 74. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 121
Table 75. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 121
Table 76. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 121
Table 77. AB Science SA: Company Snapshot 127
Table 78. AB Science SA: Business Segmentation 127
Table 79. AB Science SA: Product Portfolio 128
Table 80. AB Science SA: Revenue, 2017-2019, $ mn 128
